Analysts Set Viridian Therapeutics, Inc. (NASDAQ:VRDN) PT at $36.33

Viridian Therapeutics, Inc. (NASDAQ:VRDN - Get Free Report) has been given an average rating of "Moderate Buy" by the ten analysts that are currently covering the firm, MarketBeat.com reports. Two equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $36.33.

Several analysts recently weighed in on VRDN shares. The Goldman Sachs Group upped their price target on Viridian Therapeutics from $25.00 to $31.00 and gave the stock a "buy" rating in a research note on Thursday, September 12th. Oppenheimer reissued an "outperform" rating and issued a $28.00 target price (down previously from $31.00) on shares of Viridian Therapeutics in a report on Monday, August 12th. Royal Bank of Canada reissued an "outperform" rating and issued a $44.00 target price on shares of Viridian Therapeutics in a research report on Thursday, September 19th. Needham & Company LLC reaffirmed a "buy" rating and issued a $38.00 target price on shares of Viridian Therapeutics in a research report on Wednesday. Finally, Wedbush reaffirmed an "outperform" rating and issued a $42.00 price objective on shares of Viridian Therapeutics in a report on Monday, July 29th.

Viridian Therapeutics Trading Down 6.9 %

VRDN stock traded down $1.50 during trading on Friday, reaching $20.14. The company had a trading volume of 1,833,077 shares, compared to its average volume of 1,119,797. Viridian Therapeutics has a 52 week low of $11.40 and a 52 week high of $27.20. The company has a market cap of $1.60 billion, a P/E ratio of -4.62 and a beta of 1.10. The business has a 50 day moving average of $22.52 and a 200 day moving average of $16.92. The company has a debt-to-equity ratio of 0.05, a current ratio of 15.82 and a quick ratio of 15.82.

Insiders Place Their Bets

In related news, CEO Stephen F. Mahoney bought 21,400 shares of the stock in a transaction dated Friday, September 27th. The stock was purchased at an average cost of $23.33 per share, with a total value of $499,262.00. Following the completion of the purchase, the chief executive officer now owns 21,400 shares of the company's stock, valued at $499,262. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Fairmount Funds Management Llc acquired 1,600,000 shares of the stock in a transaction on Friday, September 13th. The stock was bought at an average cost of $18.75 per share, with a total value of $30,000,000.00. Following the completion of the transaction, the director now owns 3,445,813 shares in the company, valued at $64,608,993.75. This trade represents a 86.68 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders bought 1,626,400 shares of company stock valued at $30,616,312 over the last three months. 0.65% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the company. Quest Partners LLC increased its position in shares of Viridian Therapeutics by 344.0% during the second quarter. Quest Partners LLC now owns 6,056 shares of the company's stock worth $79,000 after purchasing an additional 4,692 shares in the last quarter. Ameritas Investment Partners Inc. boosted its holdings in Viridian Therapeutics by 19.2% in the first quarter. Ameritas Investment Partners Inc. now owns 4,961 shares of the company's stock worth $87,000 after acquiring an additional 799 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of Viridian Therapeutics during the third quarter worth about $149,000. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in shares of Viridian Therapeutics by 24.6% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 11,961 shares of the company's stock worth $156,000 after acquiring an additional 2,359 shares during the last quarter. Finally, AlphaCentric Advisors LLC increased its holdings in shares of Viridian Therapeutics by 108.3% during the second quarter. AlphaCentric Advisors LLC now owns 12,500 shares of the company's stock valued at $163,000 after acquiring an additional 6,500 shares in the last quarter.

Viridian Therapeutics Company Profile

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.